% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

  • nowwhat654 nowwhat654 Aug 18, 2013 1:10 PM Flag

    This say's it all...

    We may continue to incur substantial losses and our future profitability is uncertain.

    We began operations in 1966 and last reported net profit from 1985 through 1987. Since 1987, with a major emphasis on new drug diagnostic and development, we have incurred substantial operating losses, as we pursued our clinical trial effort to get our experimental drug, Ampligen®, approved. As of June 30, 2013, our accumulated deficit was approximately $(251,988,000). We have not yet generated significant revenues from our products and may incur substantial and increased losses in the future. We cannot assure that we will ever achieve significant revenues from product sales or become profitable. We require, and will continue to require, the commitment of substantial resources to develop our products. We cannot assure that our product development efforts will be successfully completed or that required regulatory approvals will be obtained or that any products will be manufactured and marketed successfully, or be profitable.

0.1167+0.0012(+1.04%)11:32 AMEDT